Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial
June 16, 2026
Eiger BioPharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
August 5, 2021
Related Post
-
-
Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1? Antibody
June 16, 2026
-
60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement
June 11, 2026
-
Aditxt Signed Definitive Agreement Valuing Ignite Proteomics at Approximately $150 Million
June 9, 2026